TY - JOUR T1 - M脓肿菌个体患者数据荟萃分析JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01991 -2018欧元六世- 54 - 1 SP - 1801991 AU -夸克,一家家盟——Dalcolmo Margareth Pretti AU -戴利,查尔斯·l . AU -容易的杰弗里•AU - Gayoso Regina AU -长谷川Naoki盟——Jhun Byung吸引非盟- Koh Won-Jung盟——Namkoong Ho盟——公园、Jimyung AU -汤姆森,瑞秋AU - van Ingen Jakko盟——Zweijpfenning Sanne M.H.盟,严在俊Y1 - 2019/07/01 UR - //www.qdcxjkg.com/content/54/1/1801991.abstract N2 -治疗由脓肿分枝杆菌亚种引起的肺部脓肿病(MAB-PD)。脓肿;脓肿;绵绵或脓疡子。Bolletii是具有挑战性的。我们基于报道单抗pd治疗结果的研究进行了个体患者数据元分析，以阐明单抗pd的治疗结果和每种药物对治疗结果的影响。治疗成功定义为在治疗期间培养转化≥12个月或持续培养转化无复发直至治疗结束。在14项符合条件的研究中，我们提供了8项研究的数据集，共纳入了303例单抗pd患者的分析。所有MAB-PD患者的治疗成功率为45.6%。特异性治疗成功率为33.0%。 abscessus and 56.7% for M. abscessus subsp. massiliense. For MAB-PD overall, the use of imipenem was associated with treatment success (adjusted odds ratio (aOR) 2.65, 95% CI 1.36–5.10). For patients with M. abscessus subsp. abscessus, the use of azithromycin (aOR 3.29, 95% CI 1.26–8.62), parenteral amikacin (aOR 1.44, 95% CI 1.05–1.99) or imipenem (aOR 7.96, 95% CI 1.52–41.6) was related to treatment success. For patients with M. abscessus subsp. massiliense, the choice among these drugs was not associated with treatment outcomes.Treatment outcomes for MAB-PD are unsatisfactory. The use of azithromycin, amikacin or imipenem was associated with better outcomes for patients with M. abscessus subsp. abscessus.For Mycobacterium abscessus pulmonary disease in general, imipenem use is associated with improved outcome. For M. abscessus subsp. abscessus, the use of either azithromycin, amikacin or imipenem increases the likelihood of treatment success. http://ow.ly/w24n30nSakf ER -